MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
Sotera Health Company Operating Income 2011-2026 | SHC
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Sotera Health Company
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 298 M | 277 M | 248 M | 257 M | 206 M | 184 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 298 M | 184 M | 245 M |
Quarterly Operating Income Sotera Health Company
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 80.5 M | 76.8 M | 53.2 M | 76.1 M | 63.2 M | 33.4 M | - | 63.2 M | 71.5 M | 53.5 M | - | 65.7 M | 78.3 M | 46.4 M | - | 47 M | 61.7 M | 44.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 80.5 M | 33.4 M | 61 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Brainsway Ltd.
BWAY
|
-5 M | $ 19.11 | 0.47 % | $ 99.4 M |  Israel |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Co-Diagnostics
CODX
|
-42.7 M | $ 5.31 | 4.89 % | $ 156 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 20.49 | -2.36 % | $ 215 M |  China |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 38.74 | -0.41 % | $ 1.08 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Danaher Corporation
DHR
|
4.86 B | $ 228.43 | -0.21 % | $ 167 B | USA |
 |
DexCom
DXCM
|
598 M | $ 66.86 | 0.74 % | $ 25.8 B | USA |
 |
BioNano Genomics
BNGO
|
-104 M | $ 1.56 | 1.96 % | $ 1.98 M | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
DarioHealth Corp.
DRIO
|
-56.2 M | $ 11.42 | 0.35 % | $ 324 M | Israel |
 |
IQVIA Holdings
IQV
|
2.2 B | $ 225.43 | 0.01 % | $ 40.9 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-876 M | $ 101.79 | 0.23 % | $ 18.9 B | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 25.95 | -1.24 % | $ 785 M | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
CareDx, Inc
CDNA
|
-203 M | $ 19.2 | 1.91 % | $ 1.03 B | USA |
 |
Celcuity
CELC
|
-113 M | $ 100.08 | 0.34 % | $ 3.95 B | USA |
 |
Anixa Biosciences
ANIX
|
-13.8 M | $ 3.09 | -0.96 % | $ 98.6 K | USA |
 |
Myriad Genetics
MYGN
|
-124 M | $ 6.22 | 1.14 % | $ 564 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-10.8 M | $ 4.26 | -5.96 % | $ 2.29 M | USA |
 |
NeoGenomics
NEO
|
-92.1 M | $ 11.76 | - | $ 1.49 B | USA |
 |
Guardant Health
GH
|
-444 M | $ 101.08 | -1.04 % | $ 12.4 B | USA |
 |
National Research Corporation
NRC
|
40 M | $ 18.42 | -1.89 % | $ 452 M | USA |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M | USA |
 |
OPKO Health
OPK
|
-152 M | $ 1.26 | 0.4 % | $ 874 M | USA |
 |
Precipio
PRPO
|
-7.62 M | $ 24.92 | 8.46 % | $ 32.3 M | USA |
 |
Personalis
PSNL
|
-68.3 M | $ 7.76 | -2.52 % | $ 460 M | USA |
 |
Motus GI Holdings
MOTS
|
-11.9 M | - | -34.28 % | $ 263 K | Israel |
 |
Illumina
ILMN
|
-833 M | $ 132.27 | 0.85 % | $ 21 B | USA |
 |
Charles River Laboratories International
CRL
|
227 M | $ 200.24 | 0.38 % | $ 10.3 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.35 B | $ 172.79 | -0.43 % | $ 19.2 B | USA |
|
Biodesix
BDSX
|
-34.5 M | $ 6.84 | 0.51 % | $ 887 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 27.14 | 0.22 % | $ 20 B |  Niderland |
 |
Laboratory Corporation of America Holdings
LH
|
1.09 B | $ 250.12 | -0.3 % | $ 21 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 186.86 | 2.55 % | $ 15.4 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.13 B | $ 666.09 | -1.54 % | $ 54.9 B | USA |
 |
Lantheus Holdings
LNTH
|
457 M | $ 66.89 | 0.51 % | $ 4.63 B | USA |
 |
Agilent Technologies
A
|
1.35 B | $ 136.02 | -0.04 % | $ 41.4 B | USA |